CDIO Cardio Diagnostics Holdings, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1870144 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.8%
TTM net income YoY1.0%
TTM EPS YoY21.0%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-42,649.8%
Net margin-42,721.9%
FCF margin-38,090.8%
EBITDA margin-42,499.9%
Returns
ROE-93.5%
ROA-87.2%
ROIC (approx.)-136.2%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets6.0%
Debt / equity0.00x
Current ratio17.44x
Interest coverage-564.93x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue11.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3,590 | $5,360 | $2,680 | $3,555 | $2,855 | $7,475 | $940 | $4,512 |
| R&D expense | $174,250 | $162,929 | $129,776 | $286,867 | $189,049 | $178,536 | $118,784 | $5,758 |
| SG&A expense | $1.34M | $1.14M | $1.46M | -$6,556 | $1.33M | $1.30M | $1.28M | $41,241 |
| Operating income | -$1.73M | -$1.50M | -$1.78M | -$1.46M | -$1.71M | -$1.68M | -$1.63M | -$1.52M |
| Interest expense | $2,293 | $3,440 | $3,439 | $2,292 | $3,128 | $4,690 | $4,691 | $3,127 |
| Pretax income | -$1.73M | -$1.50M | -$1.79M | -$1.47M | -$1.71M | -$1.68M | -$1.64M | -$1.52M |
| Net income | -$1.73M | -$1.50M | -$1.79M | -$1.47M | -$1.71M | -$1.68M | -$1.64M | -$1.52M |
| EBITDA | -$1.72M | -$1.49M | -$1.78M | -$1.46M | -$1.71M | -$1.67M | -$1.59M | -$1.57M |
| EPS (basic) | -0.59 | -0.51 | -0.63 | — | -0.98 | -0.97 | -0.97 | — |
| EPS (diluted) | -0.59 | -0.51 | -0.63 | — | -0.98 | -0.97 | -0.97 | — |
| Weighted avg. shares (diluted) | 2.96M | 2.96M | 2.84M | — | 1.76M | 1.74M | 1.69M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $0 | $0 | $0 | $0 | $6.36M | $7.97M | $9.69M | $7.83M |
| Receivables | $3,550 | $3,905 | $4,274 | $8,126 | $11,221 | $12,927 | $9,552 | $18,612 |
| Current assets | $4.35M | $6.16M | $7.74M | $5.92M | $6.93M | $8.70M | $10.54M | $8.79M |
| PP&E, net | $569,070 | $613,352 | $657,635 | $700,115 | $744,335 | $621,903 | $640,992 | $672,861 |
| Intangibles | — | — | — | — | — | — | $1,333 | $5,333 |
| Total assets | $6.08M | $7.93M | $9.56M | $7.77M | $8.79M | $10.40M | $12.28M | $10.62M |
| Current liabilities | $249,619 | $359,197 | $491,443 | $604,839 | $398,448 | $369,597 | $540,616 | $631,695 |
| Total liabilities | $366,002 | $499,780 | $655,972 | $793,061 | $637,331 | $671,848 | $904,998 | $1.06M |
| Shareholders' equity | $5.72M | $7.43M | $8.90M | $6.97M | $8.15M | $9.72M | $11.38M | $9.56M |
| Shares outstanding | 2.96M | 2.96M | 2.96M | 1.83M | 1.77M | 1.74M | 1.74M | 1.53M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.52M | -$1.34M | -$1.56M | -$1.36M | -$1.39M | -$1.57M | -$1.40M | -$1.39M |
| Capital expenditure | $0 | $0 | $1,760 | $0 | $162,834 | $18,696 | $5,787 | $3,638 |
| Free cash flow | -$1.52M | -$1.34M | -$1.56M | -$1.36M | -$1.56M | -$1.59M | -$1.41M | -$1.40M |
| Investing cash flow | -$60,469 | -$46,789 | -$63,696 | -$78,359 | -$257,819 | -$35,717 | -$47,415 | -$54,613 |
| Financing cash flow | -$67,448 | -$101,171 | $3.59M | $195,620 | $39,955 | -$115,037 | $3.31M | $7.29M |
| Depreciation & amortization | $5,979 | $5,593 | $5,532 | $5,655 | $5,655 | $8,485 | $45,438 | -$56,603 |
| Stock-based compensation | $24,338 | $24,352 | $24,733 | $24,083 | $24,762 | $30,778 | $30,612 | $22,415 |
Free plan shows the latest 8 periods; Pro shows all 20 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.